Selected research
Industry Growth & Trends
Global Gastric Carcinomas Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Gastric Carcinomas Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Gastric Carcinomas Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Gastric Carcinomas Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gastric Carcinomas Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Gastric Carcinomas Drugs market include Chiatai Tianqing, Fujian Haiwang Fuyao Pharmacy Limited Company, Merck & Co, Novo Nordisk, Taiho Pharmaceutical, Bayer, Jiangsu Hengrui Medicine Company Limited, Pfizer and Eli Lilly and Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Gastric Carcinomas Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Gastric Carcinomas Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Gastric Carcinomas Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Gastric Carcinomas Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Gastric Carcinomas Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Gastric Carcinomas Drugs Market by Company
Chiatai Tianqing
Fujian Haiwang Fuyao Pharmacy Limited Company
Merck & Co
Novo Nordisk
Taiho Pharmaceutical
Bayer
Jiangsu Hengrui Medicine Company Limited
Pfizer
Eli Lilly and Company
Roche
Qilu Pharma
Shandong New Era Hotel Pharmaceutical Industry Limited Company
Gastric Carcinomas Drugs Segment by Type
First Line Treatment
Second Line Treatment
Three Line Treatment
Gastric Carcinomas Drugs Segment by Application
Hospital
Clinic
Others
Gastric Carcinomas Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Carcinomas Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Carcinomas Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Carcinomas Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Gastric Carcinomas Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- First Line Treatment
- Second Line Treatment
- Three Line Treatment
Applications
- Hospital
- Clinic
- Others
Companies covered
- Chiatai Tianqing
- Fujian Haiwang Fuyao Pharmacy Limited Company
- Merck & Co
- Novo Nordisk
- Taiho Pharmaceutical
- Bayer
- Jiangsu Hengrui Medicine Company Limited
- Pfizer
- Eli Lilly and Company
- Roche
- Qilu Pharma
- Shandong New Era Hotel Pharmaceutical Industry Limited Company
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Gastric Carcinomas Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Gastric Carcinomas Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Gastric Carcinomas Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Gastric Carcinomas Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Gastric Carcinomas Drugs Market Size (2021-2032)
- 1.5.1 North America Gastric Carcinomas Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Gastric Carcinomas Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Gastric Carcinomas Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Gastric Carcinomas Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Gastric Carcinomas Drugs Market Size Growth Rate (2021-2032)
2 Gastric Carcinomas Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 First Line Treatment
- 2.1.2 Second Line Treatment
- 2.1.3 Three Line Treatment
- 2.2 Global Gastric Carcinomas Drugs Market Size by Type
- 2.2.1 Global Gastric Carcinomas Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Gastric Carcinomas Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Gastric Carcinomas Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Gastric Carcinomas Drugs Market Size by Regions
- 2.3.1 North America Gastric Carcinomas Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Gastric Carcinomas Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Gastric Carcinomas Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Gastric Carcinomas Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Gastric Carcinomas Drugs Market Size Breakdown by Type (2021-2026)
3 Gastric Carcinomas Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Clinic
- 3.1.3 Others
- 3.2 Global Gastric Carcinomas Drugs Market Size by Application
- 3.2.1 Global Gastric Carcinomas Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Gastric Carcinomas Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Gastric Carcinomas Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Gastric Carcinomas Drugs Market Size by Regions
- 3.3.1 North America Gastric Carcinomas Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Gastric Carcinomas Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Gastric Carcinomas Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Gastric Carcinomas Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Gastric Carcinomas Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Gastric Carcinomas Drugs Industry Trends
- 4.2 Gastric Carcinomas Drugs Industry Drivers
- 4.3 Gastric Carcinomas Drugs Industry Opportunities and Challenges
- 4.4 Gastric Carcinomas Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Gastric Carcinomas Drugs Revenue (2021-2026)
- 5.2 Global Gastric Carcinomas Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Gastric Carcinomas Drugs Key Company Headquarters & Area Served
- 5.4 Global Gastric Carcinomas Drugs Company, Product Type & Application
- 5.5 Global Gastric Carcinomas Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Gastric Carcinomas Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Gastric Carcinomas Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Gastric Carcinomas Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Chiatai Tianqing
- 6.1.1 Chiatai Tianqing Company Information
- 6.1.2 Chiatai Tianqing Business Overview
- 6.1.3 Chiatai Tianqing Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Chiatai Tianqing Gastric Carcinomas Drugs Product Portfolio
- 6.1.5 Chiatai Tianqing Recent Developments
- 6.2 Fujian Haiwang Fuyao Pharmacy Limited Company
- 6.2.1 Fujian Haiwang Fuyao Pharmacy Limited Company Company Information
- 6.2.2 Fujian Haiwang Fuyao Pharmacy Limited Company Business Overview
- 6.2.3 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Product Portfolio
- 6.2.5 Fujian Haiwang Fuyao Pharmacy Limited Company Recent Developments
- 6.3 Merck & Co
- 6.3.1 Merck & Co Company Information
- 6.3.2 Merck & Co Business Overview
- 6.3.3 Merck & Co Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Merck & Co Gastric Carcinomas Drugs Product Portfolio
- 6.3.5 Merck & Co Recent Developments
- 6.4 Novo Nordisk
- 6.4.1 Novo Nordisk Company Information
- 6.4.2 Novo Nordisk Business Overview
- 6.4.3 Novo Nordisk Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Novo Nordisk Gastric Carcinomas Drugs Product Portfolio
- 6.4.5 Novo Nordisk Recent Developments
- 6.5 Taiho Pharmaceutical
- 6.5.1 Taiho Pharmaceutical Company Information
- 6.5.2 Taiho Pharmaceutical Business Overview
- 6.5.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Taiho Pharmaceutical Gastric Carcinomas Drugs Product Portfolio
- 6.5.5 Taiho Pharmaceutical Recent Developments
- 6.6 Bayer
- 6.6.1 Bayer Company Information
- 6.6.2 Bayer Business Overview
- 6.6.3 Bayer Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Bayer Gastric Carcinomas Drugs Product Portfolio
- 6.6.5 Bayer Recent Developments
- 6.7 Jiangsu Hengrui Medicine Company Limited
- 6.7.1 Jiangsu Hengrui Medicine Company Limited Company Information
- 6.7.2 Jiangsu Hengrui Medicine Company Limited Business Overview
- 6.7.3 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Product Portfolio
- 6.7.5 Jiangsu Hengrui Medicine Company Limited Recent Developments
- 6.8 Pfizer
- 6.8.1 Pfizer Company Information
- 6.8.2 Pfizer Business Overview
- 6.8.3 Pfizer Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Pfizer Gastric Carcinomas Drugs Product Portfolio
- 6.8.5 Pfizer Recent Developments
- 6.9 Eli Lilly and Company
- 6.9.1 Eli Lilly and Company Company Information
- 6.9.2 Eli Lilly and Company Business Overview
- 6.9.3 Eli Lilly and Company Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Eli Lilly and Company Gastric Carcinomas Drugs Product Portfolio
- 6.9.5 Eli Lilly and Company Recent Developments
- 6.10 Roche
- 6.10.1 Roche Company Information
- 6.10.2 Roche Business Overview
- 6.10.3 Roche Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Roche Gastric Carcinomas Drugs Product Portfolio
- 6.10.5 Roche Recent Developments
- 6.11 Qilu Pharma
- 6.11.1 Qilu Pharma Company Information
- 6.11.2 Qilu Pharma Business Overview
- 6.11.3 Qilu Pharma Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Qilu Pharma Gastric Carcinomas Drugs Product Portfolio
- 6.11.5 Qilu Pharma Recent Developments
- 6.12 Shandong New Era Hotel Pharmaceutical Industry Limited Company
- 6.12.1 Shandong New Era Hotel Pharmaceutical Industry Limited Company Company Information
- 6.12.2 Shandong New Era Hotel Pharmaceutical Industry Limited Company Business Overview
- 6.12.3 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Product Portfolio
- 6.12.5 Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Developments
7 North America
- 7.1 North America Gastric Carcinomas Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 7.3 North America Gastric Carcinomas Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Gastric Carcinomas Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 8.3 Europe Gastric Carcinomas Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Gastric Carcinomas Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Gastric Carcinomas Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Gastric Carcinomas Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 10.3 South America Gastric Carcinomas Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Gastric Carcinomas Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Gastric Carcinomas Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst